Wordt geladen...
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
BACKGROUND/AIMS: Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with advanced HCC. We retrospectively analyzed a series of Korean patients with...
Bewaard in:
| Gepubliceerd in: | Clin Mol Hepatol |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
The Korean Association for the Study of the Liver
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4612290/ https://ncbi.nlm.nih.gov/pubmed/26527250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2015.21.3.287 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|